Boston University has taken a 20 percent stake in Framingham Genomic Medicine, a new company that will sell analyses of data from the university’s Framingham Heart Study.

Framingham Genomic Medicine is planning to hire a team of geneticists, biostatisticians, epidemiologists and bioinformatics specialists, who will be able to turn the genetic, clinical, and behavioral data collected from 10,000 participants over 52 years into research-quality information.